Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

108.24
+1.171.09%
Post-market: 108.240.00000.00%19:30 EDT
Volume:612.79K
Turnover:66.51M
Market Cap:5.69B
PE:26.02
High:110.50
Open:109.05
Low:107.91
Close:107.07
52wk High:111.20
52wk Low:54.66
Shares:52.57M
Float Shares:51.78M
Volume Ratio:1.07
T/O Rate:1.18%
Dividend:0.32
Dividend Rate:0.30%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.48
PE(LYR):100.22

Loading ...

Analysts Offer Insights on Materials Companies: TRONOX (TROX), Westlake Corporation (WLK) and Warrior Met Coal (HCC)

TIPRANKS
·
Aug 06

Core Natural Resources Q2 Ebitda Beats Estimates

Reuters
·
Aug 06

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

GlobeNewswire
·
Aug 06

Warrior Met Coal Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Warrior Met Coal Q2 Revenue Jumps 71% as Blue Creek Mine Boosts Volumes

Reuters
·
Aug 06

Warrior Met Coal Q2 Net Income USD 87.4 Million

Reuters
·
Aug 06

Warrior Met Coal Q2 EPS $1.65 Beats $1.55 Estimate, Sales $509.690M Beat $488.358M Estimate

Benzinga Earnings
·
Aug 06

Warrior Met Coal - Full Year 2026 Coal Sales Guidance 13.0-14.0 Mln Short Tons

THOMSON REUTERS
·
Aug 06

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

GlobeNewswire
·
Aug 03

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

GlobeNewswire
·
Aug 03

Earning Preview: Warrior Met Coal LLC this quarter’s revenue is expected to increase by 66.90%, and institutional views are bullish

Earnings Agent
·
Jul 29

Warrior Met Coal Keeps Quarterly Dividend at $0.08 a Share, Payable Aug. 17 to Holders of Record Aug. 10

MT Newswires Live
·
Jul 29

Press Release: Warrior Announces Regular Quarterly Cash Dividend

Dow Jones
·
Jul 29

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

GlobeNewswire
·
Jul 22

Coal Sector Urges Trump Administration to Provide Financing for Existing, New Power Plants

Reuters
·
Jul 22

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

GlobeNewswire
·
Jul 20

3 U.S. Manufacturing Stocks Investors Are Watching As Brazil Tariffs Hit

Simply Wall St.
·
Jul 20

Warrior Met Coal Schedules Q2 Earnings Release, Investor Call

Reuters
·
Jul 16

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

GlobeNewswire
·
Jul 14

Blue Creek Completion and Supply Constraints Could Be A Game Changer For Warrior Met Coal (HCC)

Simply Wall St.
·
Jul 12